A detailed history of Morgan Stanley transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Morgan Stanley holds 1,349,381 shares of NBIX stock, worth $166 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,349,381
Previous 1,544,869 12.65%
Holding current value
$166 Million
Previous $213 Million 26.95%
% of portfolio
0.01%
Previous 0.02%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $22.4 Million - $29.9 Million
-195,488 Reduced 12.65%
1,349,381 $155 Million
Q2 2024

Oct 17, 2024

SELL
$130.86 - $143.19 $68.1 Million - $74.6 Million
-520,767 Reduced 25.21%
1,544,869 $213 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $68.1 Million - $74.6 Million
-520,767 Reduced 25.21%
1,544,869 $213 Million
Q1 2024

Oct 17, 2024

BUY
$130.4 - $143.74 $67.9 Million - $74.9 Million
520,767 Added 33.71%
2,065,636 $285 Million
Q1 2024

Aug 16, 2024

SELL
$130.4 - $143.74 $34 Million - $37.5 Million
-260,658 Reduced 11.2%
2,065,636 $285 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $34 Million - $37.5 Million
-260,658 Reduced 11.2%
2,065,636 $285 Million
Q4 2023

Aug 16, 2024

BUY
$106.07 - $132.76 $82.9 Million - $104 Million
781,425 Added 50.58%
2,326,294 $307 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $42.7 Million - $53.4 Million
402,215 Added 20.9%
2,326,294 $307 Million
Q3 2023

Nov 15, 2023

BUY
$94.02 - $117.1 $5.27 Million - $6.56 Million
56,054 Added 3.0%
1,924,079 $216 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $19.1 Million - $22.4 Million
213,132 Added 12.88%
1,868,025 $176 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $37 Million - $48.4 Million
-393,192 Reduced 19.2%
1,654,893 $168 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $161 Million - $192 Million
1,511,307 Added 281.55%
2,048,085 $245 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $4.56 Million - $5.34 Million
49,503 Added 10.16%
536,778 $57 Million
Q2 2022

Oct 27, 2022

BUY
$75.79 - $100.07 $23.5 Million - $31.1 Million
310,448 Added 175.57%
487,275 $47.5 Million
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $23.5 Million - $31.1 Million
310,448 Added 175.57%
487,275 $47.5 Million
Q1 2022

Oct 27, 2022

SELL
$72.45 - $94.81 $22.5 Million - $29.4 Million
-310,448 Reduced 63.71%
176,827 $16.6 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $2.71 Million - $3.55 Million
37,462 Added 26.88%
176,827 $16.6 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $440,145 - $586,971
-5,526 Reduced 3.81%
139,365 $11.9 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $12.5 Million - $14.3 Million
144,891 New
144,891 $13.9 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.